Paddock ORA-BLEND - Perrigo Company

January 30, 2018 | Author: Anonymous | Category: N/A
Share Embed


Short Description

Look to Paddockfor All of Your CompoundingNeeds ORA-BLEND Ora-Blend is a flavored oral suspending vehicle used to simpli...

Description

T O P I C A L S

Look to Paddock for All of Your Compounding Needs

I N J E C T A B L E S O R A L O R A L

L I Q U I D S S O L I D S

S U P P O S I T O R I E S C O M P O U N D I N G

ORA-BLEND

®

ORA-BLEND

®

Flavored Oral Suspending Vehicle Paddock ORA-BLEND Size

NDC

473 ML (One Pint)

0574-0311-16

Ora-Blend is a flavored oral suspending vehicle used to simplify the process involved in the extemporaneous compounding of oral suspensions. Medicated powder can be incorporated into Ora-Blend to form elegant, uniform and physically stable suspensions.

Applications

®

Ingredients

Ora-Blend combines the suspending properties of Ora-Plus ® with the flavoring agents of Ora-Sweet and is ideal for: • Pediatric suspensions • Geriatric suspensions

Purified water, sucrose, glycerin, sorbitol, flavoring, microcrystalline cellulose, carboxymethylcellulose sodium, xanthan gum, carrageenan, calcium sulfate, trisodium phosphate, citric acid and sodium phosphate as buffers, dimethicone antifoam emulsion. Preserved with methylparaben and potassium sorbate.

Properties

Specifications

Ora-Blend is an aqueous-based, sweetened vehicle consisting of a synergistic blend of suspending agents that have a high degree of colloidal activity. The suspending agents form a structured, gel-like matrix which suspend particles and allow for little settling. Ora-Blend is buffered to a slightly acidic pH to help reduce degradation of medicinal agents through oxidation. An anti-foam agent is incorporated into Ora-Blend to allow for vigorous shaking with minimal foam.

Appearance: Opaque, pinkish liquid with a pH of approximately 4.2 Taste: Sweet citrus-berry flavor Viscosity: Approximately 700 cps at 25°C via Brookfield viscometer Osmolality: 2107 mOsm/Kg Order through your wholesaler. For additional information please contact Paddock Laboratories at 1-800-328-5113 or www.paddocklabs.com

© 2010 PADDOCK LABORATORIES, LLC 0311-05-0310

Now part of the Perrigo Family

ORA-BLEND Formulating and Compounding Examples ADDERALL 1 mg/mL3, 100 mL Adderall 10 mg/tablet Ora-Blend • Expiration 30 days at 25°C • Protect from light • Shake well before using

TIAGABINE 1 mg/mL4, 120 mL 10 tablets q.s. 100 mL

TERBINAFINE HYDROCHLORIDE 25 mg/mL2, 100 mL Terbinafine HCI 250 mg/tablet 10 tablets Ora-Blend q.s. 100 mL • Expiration 42 days at either 4°C or 25°C • Protect from light • Shake well before using

Tiagabine 12 mg/tablet 10 tablets Ora-Blend q.s. 120 mL • Expiration 70 days at 25°C or 91 days at 4°C • Protect from light • Shake well before using

VALGANCICLOVIR 30 mg/mL, (as the HCI salt)1, 90 mL Valganciclovir 450 mg/tablet Ora-Blend • Expiration 35 days at 4°C • Refrigerate • Protect from light • Shake well before using

6 tablets q.s. 90 mL

General Directions For Compounding ORA-BLEND Suspensions

• Calculate the total amount of active ingredient and volume of solution needed to create a suspension of the proper concentration. (Calculations are provided in the examples above.) It may be wise to add approximately 10% overage for compounding losses.

1

• Crush tablets with a mortar and pestle to a fine powder. If the compound is already in the powder form, use the mortar and pestle to smooth out the powder.

Contraindications

• Add a small amount of Ora-Blend and triturate to a thick, smooth paste. Add the remainder of Ora-Blend by geometric dilution. • Mix briefly with a mortar and pestle until a uniform suspension is formed. • Dispense in a tight, light resistant amber bottle with appropriate labeling. • Label with an expiration date. If the stability of the medication in an oral suspension or syrup is unknown, conservative dating is suggested.

American Journal of Health-System Pharmacists 2003; 60:687-90. American Journal of Health-System Pharmacists 1999; 56:243-5. 3 American Journal of Health-System Pharmacists 2001; 58:1418-21. 4 American Journal of Health-System Pharmacists 2003; 60:75-7. 2

Ora-Blend is contraindicated in persons who have shown hypersensitivity to any of the listed ingredients. All information presented is intended to demonstrate the application of Paddock vehicles for compounding. Paddock products are sold on the understanding that purchasers will make their own determinations as to the suitability, safety and effectiveness of their applications. The uses presented by Paddock are only to assist our customers in exploring possible applications. All information and data presented are believed to be accurate and reliable, but are presented without the assumption of any liability by Paddock Laboratories. Paddock Laboratories does not warrant against infringements of patents of third parties by reason of any uses made of the vehicles in combination with other material or in the operation of any process, and purchasers assume all risks of patent infringement by reason of any such use, combination or operation.

• Depending on the medicinal agent used, label containers "Shake Well Before Using," "Protect From Light," and "Keep Refrigerated."

Now part of the Perrigo Family

View more...

Comments

Copyright © 2017 KINPDF Inc.